CN102058613A - New application of antineoplastic constituent compound in solanum nigrum - Google Patents
New application of antineoplastic constituent compound in solanum nigrum Download PDFInfo
- Publication number
- CN102058613A CN102058613A CN2011100053503A CN201110005350A CN102058613A CN 102058613 A CN102058613 A CN 102058613A CN 2011100053503 A CN2011100053503 A CN 2011100053503A CN 201110005350 A CN201110005350 A CN 201110005350A CN 102058613 A CN102058613 A CN 102058613A
- Authority
- CN
- China
- Prior art keywords
- solamargine
- solasonine
- group
- weight ratio
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000061457 Solanum nigrum Species 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 title abstract description 3
- 235000002594 Solanum nigrum Nutrition 0.000 title description 2
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 239000000470 constituent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 8
- 201000007270 liver cancer Diseases 0.000 claims abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 6
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 claims description 34
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 claims description 33
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 claims description 31
- KNLOWJPFLKGYGQ-UHFFFAOYSA-N Solasodine 3-O-??-L-rhamnopyranosyl (1‘Â∆2)-O-[??-D-glucopyranosyl (1‘Â∆4)]-??-D-glucopyranoside Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O KNLOWJPFLKGYGQ-UHFFFAOYSA-N 0.000 claims description 30
- QCTMYNGDIBTNSK-UHFFFAOYSA-N Solasonin Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O QCTMYNGDIBTNSK-UHFFFAOYSA-N 0.000 claims description 30
- QCTMYNGDIBTNSK-QCNFCIKQSA-N Solasonine Natural products O([C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@@H](C)[C@@]7(O[C@H]6C5)NC[C@H](C)CC7)CC4)CC=3)CC2)O[C@@H](CO)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QCTMYNGDIBTNSK-QCNFCIKQSA-N 0.000 claims description 30
- RCTKRNCKOYYRIO-UHFFFAOYSA-N alpha-Solamarine Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O RCTKRNCKOYYRIO-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 14
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 3
- 229940090044 injection Drugs 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 239000002131 composite material Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 10
- 239000012362 glacial acetic acid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 239000000178 monomer Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- KWVISVAMQJWJSZ-VKROHFNGSA-N solasodine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 KWVISVAMQJWJSZ-VKROHFNGSA-N 0.000 description 2
- JXWLYDNHVXFBJA-UHFFFAOYSA-N solasodine Natural products CC1CCC2(NC1)NC3CC4C5CC=C6CC(O)CCC6(C)C5CCC4(C)C3C2C JXWLYDNHVXFBJA-UHFFFAOYSA-N 0.000 description 2
- 229930003352 steroid alkaloid Natural products 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000011728 BALB/c nude (JAX™ mouse strain) Methods 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930008677 glyco alkaloid Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of ratio compounds of two simplex components in plant solanum nigrum extracts to preparing medicaments for treating liver cancer.
Description
Technical field
The present invention relates to the application of ratio compositions in preparation treatment liver-cancer medicine of two monomer components in the plant black nightshade extract, described monomer component is respectively solamargine and solasonine.
Background technology
Herba Solani Nigri Solalum Nigrum L. is annual Solanum herbaceous plant, and all there is growth most of at home provinces and regions.The herb hyoscine, cold in nature, bitter in the mouth is hot little sweet, slightly poisonous, returns lung, urinary bladder channel.Can dissipating blood stasis for subsidence of swelling, heat-clearing and toxic substances removing has the effect of anticancer, and treatment pain commonly used is swollen, tumor etc.Herba Solani Nigri also has certain dietary function in addition, therefore has good medical value.Be rich in steroid alkaloid in the plant, these steroid alkaloids all are present in Solanum nigrum stem, leaf, root, really with the form of glycosides, and aglycon is solasodine (solasodine).
Solasonine (solasonine, CAS 19121-58-5) and solamargine (solamargine, CAS 20311-51-7) is two main in Herba Solani Nigri alkaloid components, in in vitro tests, two chemical compounds all show the destructiveness of cell membrane fat, both show cooperative effect, the destructiveness of solamargine is stronger, rhamnose wherein may play important function in the combining of guiding glycoalkaloid and cell, some studies show that solamargine, thereby solamargine can be regulated the expression of Tumor Necrosis Factor Receptors and cause cancer cell-apoptosis, and 2 rhamnose may play a decisive role in triggering natural death of cerebral cells.
Solasonine (solasonine)
Solamargine (solamargine)
WO2004002497 discloses solasonine (solasonine) and the experiment in vitro result of solamargine (solamargine) compositions in A2058 (human melanoma cell), NO36, LS174T (human colon cancer cell), LNCaP (Human Prostate Cancer Cells), 786-O tumor cell lines such as (people's kidney clear cell adenocarcinoma cells) and NHDF-Ad (normal adult skin flbroblast), NHRE.The application in the treatment liver-cancer medicine of unexposed solasonine of this application (solasonine) and solamargine (solamargine) compositions, the prompting of also not being correlated with.
Summary of the invention
The present invention relates to the application of ratio compositions in preparation treatment liver-cancer medicine of two monomer components in the plant black nightshade extract, described monomer component is respectively solamargine and solasonine.
The weight ratio of solamargine and solasonine is 1: 1-10: 1, and preferred weight ratio is 2: 1～10: 1, preferred weight ratio is 4: 1～10: 1.The weight ratio of further preferred solamargine and solasonine is 6.5: 1～7.5: 1, and weight ratio is further more preferably from 6.5: 1 or 7: 1 or 7.5: 1.
Can also contain solvent in the above-mentioned pharmaceutical composition, can be so that solasonine and solamargine mix better.Described solvent can be selected the mixture of water, water-miscible organic solvent or water-miscible organic solvent and water for use.Water-miscible organic solvent commonly used mainly contains alcohols solvent, ether solvent, ketones solvent etc.The mixture of solvent preferred water, water-miscible organic solvent and water among the present invention.Be more preferably the glacial acetic acid aqueous solution of low concentration.
Beneficial effect of the present invention has been to provide a kind of solamargine and the application of solasonine compositions in preparation treatment liver-cancer medicine.The solamargine of preferred proportion and solasonine compositions table reveal lower toxicity among the present invention, and can effectively reduce relative tumor proliferation rate with respect to blank group, single medicine group.
The specific embodiment
The invention will be further described in the mode of embodiment below, provides implementation detail of the present invention, but be not to be intended to limit protection scope of the present invention.
The preparation of embodiment 1 injection
Solasonine injection: get solasonine 140mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Solamargine injection: get solamargine 140mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection A (weight ratio 4: 1): get solamargine 112mg and solasonine 28mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection B (weight ratio 7: 1): get solamargine 122.5mg and solasonine 17.5mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection C (weight ratio 4: 1): get solamargine 56mg and solasonine 14mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection D (weight ratio 7: 1): get solamargine 60.9mg and solasonine 8.7mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection E (weight ratio 4: 1): get solamargine 168mg and solasonine 42mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Composite injection F (weight ratio 7: 1): get solamargine 184.1mg and solasonine 26.3mg, add slowly that 1.5% glacial acetic acid solution makes it dissolving and to 100mL, promptly.
Embodiment 2 sets up HepG2 transplanted tumor in nude mice model
Recovery and amplification HepG2 cell; To be amplified to enough cells, collecting cell, to be made into concentration be 2 * 10 with not containing 1640 of serum
7The cell suspension of cell/ml.
Select 60 of BALB/c-nude nude mouses (SPF level, 5-6 age in week, male); The right side subcutaneous vaccination of nude mice back, 0.1ml/, promptly every nude inoculation cell number is 2 * 10
6Observe out tumor situation and tumor size after the inoculation.
The contrast of embodiment 3 effects
3.1 grouping: treat that tumor grows to volume 150mm
3During the left and right sides, select from 60 nude mices that 36 gross tumor volumes are close, shape nude mice preferably, be divided into 6 groups, 6 every group.
Group 1: matched group, give 1.5% glacial acetic acid solution, per 10 gram body weight lumbar injection 0.1ml, every administration then stops administration four days, totally 3 weeks after three days.
Group 2: give positive drug--cisplatin injection (concentration 0.6mg/ml), per 10 gram body weight lumbar injection 0.1ml, 1 time weekly, totally 3 weeks.
Group 3～group 6 gives the part injection of configuration among the embodiment 1, per 10 gram body weight lumbar injection 0.1ml, and every administration then stops administration four days, totally 3 weeks after three days.Wherein organize 3 and give the solasonine injection; Group 4 gives the solamargine injection; Group 5 gives composite injection A, and group 6 gives composite injection B.
3.2 administration: grouping back administration on the same day, be made as Day1, administering mode is the same.
3.3 measure: measure gross tumor volume weekly 3 times, Day21 puts to death nude mice, calculates relative tumor proliferation rate.
3.4 detect index and computational methods
(tumor volume, TV), computing formula is gross tumor volume
L wherein
1, l
2Represent length and width respectively.
(relative tumor volume, RTV), computing formula is relative tumour volume
TV wherein
1(Day1) gross tumor volume during for minute cage administration, TV
tGross tumor volume when measuring each time.
Relative tumor proliferation rate T/C (%), computing formula is
Wherein RTC (T) is treatment group RTV; RTC (C) is blank group RTV.
Drug effect result to people's hepatocarcinoma HepG2 Nude Mice
*: P＜0.05 * *: P＜0.01, compare with the blank group
Experimental result shows composite injection A group dead 2 nude mices altogether, animal dead does not appear in composite injection B group, but weight loss 16.9%, from mortality rate and weight loss rate, in this experiment under this dosage composite injection A group toxicity stronger, composite injection B group toxicity relatively a little less than.
From relative tumor proliferation rate drug effect, composite injection A group all shows certain tumor killing effect with composite injection B group, but both drug effect no difference of science of statistics.
In this experiment, consider from relative tumor proliferation rate, mortality rate, weight loss percentage ratio three aspects that each group of monomer and mixture compares, composite injection B group shows preferably tumor proliferation rate and more weak toxicity relatively.According to drug research technological guidance principle, antitumor drug therapeutic evaluation standard T/C%≤60%, and process statistical procedures p＜0.05 is effective.Under 14mg/kg dosage, monomer and mixture drug effect toxicity compare, and composite injection B group has certain tumor killing effect to HepG2 people's cancer bare mouse different species transplanted tumor, also shows more weak toxicity.
Claims (7)
1. solamargine and the solasonine compositions application in preparation treatment liver-cancer medicine.
2. according to the application described in the claim 1, the weight ratio that it is characterized in that solamargine and solasonine is 1:1～10:1.
3. according to the application described in the claim 1, the weight ratio that it is characterized in that solamargine and solasonine is 2:1～10:1.
4. according to the application described in the claim 1, the weight ratio that it is characterized in that solamargine and solasonine is 4:1～10:1.
5. according to the application described in the claim 1, the weight ratio that it is characterized in that solamargine and solasonine is 6.5:1～7.5:1.
6. according to the application described in the claim 1, the weight ratio that it is characterized in that solamargine and solasonine is 6.5:1 or 7:1 or 7.5:1.
7. according to each described application among the claim 1-6, it is characterized in that described compositions can also comprise other pharmaceutically acceptable inactive ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110005350.3A CN102058613B (en) | 2011-01-12 | 2011-01-12 | The purposes of anti-tumor active ingredient compositions in Herba Solani Nigri |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110005350.3A CN102058613B (en) | 2011-01-12 | 2011-01-12 | The purposes of anti-tumor active ingredient compositions in Herba Solani Nigri |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058613A true CN102058613A (en) | 2011-05-18 |
| CN102058613B CN102058613B (en) | 2015-12-16 |
Family
ID=43994239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110005350.3A Active CN102058613B (en) | 2011-01-12 | 2011-01-12 | The purposes of anti-tumor active ingredient compositions in Herba Solani Nigri |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058613B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112957364A (en) * | 2021-03-29 | 2021-06-15 | 杭州立效生物医药科技有限公司 | Medicine for treating renal tubular injury and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247715A1 (en) * | 2003-06-05 | 2004-12-09 | G & E Herbal Biotechnology Co., Ltd. | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
-
2011
- 2011-01-12 CN CN201110005350.3A patent/CN102058613B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247715A1 (en) * | 2003-06-05 | 2004-12-09 | G & E Herbal Biotechnology Co., Ltd. | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
Non-Patent Citations (1)
| Title |
|---|
| KAP-RANG LEE, ET AL.: "Glycoalkaloids and Metabolites Inhibit the Growth of Human Colon (HT29) and Liver (HepG2) Cancer Cells", 《J. AGRIC. FOOD CHEM.》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112957364A (en) * | 2021-03-29 | 2021-06-15 | 杭州立效生物医药科技有限公司 | Medicine for treating renal tubular injury and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058613B (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375037B2 (en) | Pharmaceutical composition containing crude drugs (組成) | |
| CN105078956A (en) | Application of forsythin aglycone in preparing medicine for preventing or treating liver injury or liver failure | |
| CN103989695B (en) | A kind of pharmaceutical composition and application thereof treating bronchial asthma | |
| CN108815218A (en) | Medical composition and its use | |
| CN110585233B (en) | Antitumor composition and pharmaceutical application thereof | |
| CN103908611A (en) | Traditional Chinese medicine preparation for treating colon cancer and preparation method of traditional Chinese medicine preparation | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN110025705A (en) | A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis | |
| CN103816448B (en) | A kind of Chinese medicine composition treating pulmonary tuberculosis | |
| CN102058613B (en) | The purposes of anti-tumor active ingredient compositions in Herba Solani Nigri | |
| CN105168500A (en) | Pharmaceutical composition used for curing infantile dental ulcer and preparation method for pharmaceutical composition | |
| CN107496525A (en) | A kind of Chinese medicine composition for treating cancer pain disease and its application | |
| CN104095904B (en) | A kind of pharmaceutical composition for treating courage relevant disease, preparation method and its usage | |
| CN102526387B (en) | Medicinal composition for treating early-stage diabetic foot and preparation method thereof | |
| CN108721442B (en) | Traditional Chinese medicine composition and preparation for treating burns, scalds and diaper dermatitis and preparation method thereof | |
| CN106138697B (en) | Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients | |
| CN103251869B (en) | Traditional Chinese medicinal psoralen-containing composition for treating stomach cancer and preparation method and application thereof | |
| CN104666927A (en) | Traditional Chinese medicine composition and application thereof in regulating human immune functions and/or resisting tumors | |
| CN109663012A (en) | Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof | |
| CN103263475A (en) | Traditional chinese medicine composition | |
| CN103341109A (en) | Natural drug extract and preparation method thereof | |
| CN103566058B (en) | A kind of double blue or green composition of medicine, preparation method and applications | |
| CN103356769A (en) | Natural drug extract, preparation method and application thereof | |
| CN102552440A (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN105963423A (en) | Pharynx-heat-clearing and larynx-moistening soft capsule preparation and method for preparing pharynx-heat-clearing and larynx-moistening soft capsule preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Address before: 210042 -18, Xuanwu Avenue, Xuanwu District, Jiangsu, Nanjing, 669 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150625 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150625 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160711 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201229 Address after: 570311 No. 2 Yaogu No. 3 Road, Xiuying District, Haikou City, Hainan Province Patentee after: Hainan Simcere Pharmaceutical Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |